Sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor analogs (GLP1-RA) have been a “game changer” in diabetes management because they demonstrate significant reductions in CV morbidity and mortality in patients with established atherosclerotic CV disease, heart failure, and reduced kidney function [10–18]. The gene discussed is GLP1R; the disease is heart failure.